StockTipsArenaBeta

SELL Zydus Lifesciences Limited — Rachna Vaidya

SELLZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byRachna VaidyaHorizon: NA (inferred Intraday)30 Sept 2026, 9:24 am ISTvia CNBC Awaaz.

Entry₹1,196.8Inferred
Target₹1,190
Total upside +0.57% (call closed)
Stop loss₹1,212-1.27% risk
Exit₹1,19030 Sept 2026, 9:33 am
Target hit+0.57%0.00%upside left
Follow Rachna Vaidya for new calls(17% target hit, 46 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Sept 2026
0 supporting2 neutral4 opposing
Supports the SELL call (0)

Nothing found in this tip’s window yet.

Neutral / worth noting (2)

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · today

(opens in new tab)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 5d ago

(opens in new tab)
Weighs against the SELL call (4)

The USFDA concluded a cGMP inspection at the company's SEZ II manufacturing plant in Ahmedabad with only one observation and no data integrity issues.

BSE · Company Update·28 Sept · yesterday

(opens in new tab)

6 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·29 Sept · yesterday

Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

NewsCnbc-Tv18·26 Sept · 3d ago

(opens in new tab)

The USFDA inspection of Zydus Lifesciences' USA office for pharmacovigilance and post-marketing systems concluded with no observations.

BSE · Company Update·26 Sept · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Rachna Vaidya

Every call and its outcome